PD-166285 | CAS#212391-63-4 | protein tyrosine kinase inhibitor

MedKoo Cat#: 525796 | Name: PD-166285

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

PD-166285 is a potent and broadly active protein tyrosine kinase inhibitor. PD-166285 is a G2/M cell cycle arrest inhibitor. PD-166285 has been characterized as a novel G2 abrogator and Wee 1 inhibitor.

Chemical Structure

PD-166285

CAS#212391-63-4 (HCl)

Theoretical Analysis

MedKoo Cat#: 525796

Name: PD-166285

CAS#: 212391-63-4 (HCl)

Chemical Formula: C26H29Cl4N5O2

Exact Mass: 583.1075

Molecular Weight: 585.35

Elemental Analysis: C, 53.35; H, 4.99; Cl, 24.22; N, 11.96; O, 5.47

Price and Availability

Size	Price	Availability
5mg	USD 275.00	2 Weeks
10mg	USD 490.00	2 Weeks
25mg	USD 900.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

185039-89-8 (free base) 212391-63-4 (HCl)

Synonym

PD-166285; PD 166285; PD166285; PD-166285 HCl; PD-166285 dihydrochloride

IUPAC/Chemical Name

6-(2,6-Dichlorophenyl)-2-[4-[2-(diethylamino)ethoxy]anilino]-8-methylpyrido[2,3-d]pyrimidin-7-one dihydrochloride

InChi Key

NADLBPWBFGTESN-UHFFFAOYSA-N

InChi Code

InChI=1S/C26H27Cl2N5O2.2ClH/c1-4-33(5-2)13-14-35-19-11-9-18(10-12-19)30-26-29-16-17-15-20(25(34)32(3)24(17)31-26)23-21(27)7-6-8-22(23)28;;/h6-12,15-16H,4-5,13-14H2,1-3H3,(H,29,30,31);2*1H

SMILES Code

O=C1C(C2=C(Cl)C=CC=C2Cl)=CC3=CN=C(NC4=CC=C(OCCN(CC)CC)C=C4)N=C3N1C.[H]Cl.[H]Cl

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

PD-166285 is a potent and broadly active protein tyrosine kinase inhibitor.

In vitro activity:

A pyridopyrimidine class of molecule, PD0166285 was identified that inhibited Wee1 at a nanomolar concentration. At the cellular level, 0.5 microM PD0166285 dramatically inhibits irradiation-induced Cdc2 phosphorylation at the Tyr-15 and Thr-14 in seven of seven cancer cell lines tested. PD0166285 abrogates irradiation-induced G(2) arrest as shown by both biochemical markers and fluorescence-activated cell sorter analysis and significantly increases mitotic cell populations. Reference: Cancer Res. 2001 Nov 15;61(22):8211-7. https://pubmed.ncbi.nlm.nih.gov/11719452/

In vivo activity:

In vivo anti-angiogenesis studies in mice revealed that oral administration (p.o.) of either PD166285 (1-25 mg/kg) or PD173074 (25-100 mg/kg) generated dose dependent inhibition of angiogenesis. Against a murine mammary 16c tumor, significantly prolonged tumor regressions were achieved with daily p.o. doses of PD166285 (5-10 mg/kg) or PD173074 (30-60 mg/kg) following PDT compared with PDT alone (p<0.001). Reference: Invest New Drugs. 1999;17(2):121-35. https://pubmed.ncbi.nlm.nih.gov/10638483/

	Solvent	mg/mL	mM
Solubility
	DMSO	58.5	100.00

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 585.35 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Wang Y, Li J, Booher RN, Kraker A, Lawrence T, Leopold WR, Sun Y. Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator. Cancer Res. 2001 Nov 15;61(22):8211-7. PMID: 11719452. 2. Panek RL, Lu GH, Klutchko SR, Batley BL, Dahring TK, Hamby JM, Hallak H, Doherty AM, Keiser JA. In vitro pharmacological characterization of PD 166285, a new nanomolar potent and broadly active protein tyrosine kinase inhibitor. J Pharmacol Exp Ther. 1997 Dec;283(3):1433-44. PMID: 9400019. 3. Dimitroff CJ, Klohs W, Sharma A, Pera P, Driscoll D, Veith J, Steinkampf R, Schroeder M, Klutchko S, Sumlin A, Henderson B, Dougherty TJ, Bernacki RJ. Anti-angiogenic activity of selected receptor tyrosine kinase inhibitors, PD166285 and PD173074: implications for combination treatment with photodynamic therapy. Invest New Drugs. 1999;17(2):121-35. doi: 10.1023/a:1006367032156. PMID: 10638483.

In vitro protocol:

In vivo protocol:

1. Dimitroff CJ, Klohs W, Sharma A, Pera P, Driscoll D, Veith J, Steinkampf R, Schroeder M, Klutchko S, Sumlin A, Henderson B, Dougherty TJ, Bernacki RJ. Anti-angiogenic activity of selected receptor tyrosine kinase inhibitors, PD166285 and PD173074: implications for combination treatment with photodynamic therapy. Invest New Drugs. 1999;17(2):121-35. doi: 10.1023/a:1006367032156. PMID: 10638483.

1: Pichard A, Marcatili S, Karam J, Constanzo J, Ladjohounlou R, Courteau A, Jarlier M, Bonnefoy N, Patzke S, Stenberg V, Coopman P, Cartron G, Navarro- Teulon I, Repetto-Llamazares A, Heyerdahl H, Dahle J, Bardiès M, Pouget JP. The therapeutic effectiveness of 177Lu-lilotomab in B-cell non-Hodgkin lymphoma involves modulation of G2/M cell cycle arrest. Leukemia. 2020 May;34(5):1315-1328. doi: 10.1038/s41375-019-0677-4. Epub 2019 Dec 13. PMID: 31836849; PMCID: PMC7192854. 2: Leijen S, Beijnen JH, Schellens JH. Abrogation of the G2 checkpoint by inhibition of Wee-1 kinase results in sensitization of p53-deficient tumor cells to DNA-damaging agents. Curr Clin Pharmacol. 2010 Aug;5(3):186-91. doi: 10.2174/157488410791498824. PMID: 20406171. 3: Furet P, Caravatti G, Guagnano V, Lang M, Meyer T, Schoepfer J. Entry into a new class of protein kinase inhibitors by pseudo ring design. Bioorg Med Chem Lett. 2008 Feb 1;18(3):897-900. doi: 10.1016/j.bmcl.2007.12.041. Epub 2008 Jan 14. PMID: 18248988. 4: Lavelle F. American Association for Cancer Research 1999: 10-14 April, Philadelphia, Pennsylvania. Expert Opin Investig Drugs. 1999 Jun;8(6):903-9. doi: 10.1517/13543784.8.6.903. PMID: 15992139. 5: Dimitroff CJ, Klohs W, Sharma A, Pera P, Driscoll D, Veith J, Steinkampf R, Schroeder M, Klutchko S, Sumlin A, Henderson B, Dougherty TJ, Bernacki RJ. Anti- angiogenic activity of selected receptor tyrosine kinase inhibitors, PD166285 and PD173074: implications for combination treatment with photodynamic therapy. Invest New Drugs. 1999;17(2):121-35. doi: 10.1023/a:1006367032156. PMID: 10638483. 6: Roginskaya V, Zuo S, Caudell E, Nambudiri G, Kraker AJ, Corey SJ. Therapeutic targeting of Src-kinase Lyn in myeloid leukemic cell growth. Leukemia. 1999 Jun;13(6):855-61. doi: 10.1038/sj.leu.2401429. PMID: 10360372. 7: Panek RL, Lu GH, Klutchko SR, Batley BL, Dahring TK, Hamby JM, Hallak H, Doherty AM, Keiser JA. In vitro pharmacological characterization of PD 166285, a new nanomolar potent and broadly active protein tyrosine kinase inhibitor. J Pharmacol Exp Ther. 1997 Dec;283(3):1433-44. PMID: 9400019.